Favipiravir and/or Nitazoxanide: a Randomized, Double-blind, Placebo-controlled Trial of Early Antiviral Therapy in COVID-19 (FANTAZE)

Smith et al., NCT04918927, FANTAZE, NCT04918927, Mar 2023
120 patient nitazoxanide early treatment RCT with results not reported over 2 years after completion.
The protocol has been published1.
Important missing comments or errors? Let us know.
Study covers favipiravir and nitazoxanide.
Smith et al., 21 Mar 2023, Double Blind Randomized Controlled Trial, Mexico, trial NCT04918927 (history) (FANTAZE). Contact: jorgeep@unam.mx.
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0